In his letter, Christoph Laske, MD, raises several pertinent points in reference to our recent article1 that are applicable to most, if not all, published blood-based biomarker studies in the field of Alzheimer disease (AD).
Laske correctly identifies that the perfect biomarker panel remains elusive, with very few candidates remaining consistent across studies. A study's final panel may lack extensive overlap, but this may simply be owing to the lack of analysis of a given protein rather than its lack of association, the case in point being the comparison of variables analyzed in both data sets in our study.1 Caution should be taken when discounting candidate biomarkers based on lack of overlap in most published panels.
Laws SM, Doecke JD, Martins RN. Blood-Based Biomarkers in Alzheimer Disease: Where Are We Now and Where Have We to Go?—Reply. JAMA Neurol. 2013;70(1):133–134. doi:10.1001/jamaneurol.2013.709
Customize your JAMA Network experience by selecting one or more topics from the list below.